2,189 reports of this reaction
2.3% of all ENOXAPARIN SODIUM reports
#5 most reported adverse reaction
ANAEMIA is the #5 most commonly reported adverse reaction for ENOXAPARIN SODIUM, manufactured by Sanofi-Aventis U.S. LLC. There are 2,189 FDA adverse event reports linking ENOXAPARIN SODIUM to ANAEMIA. This represents approximately 2.3% of all 96,320 adverse event reports for this drug.
Patients taking ENOXAPARIN SODIUM who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is a less commonly reported adverse event for ENOXAPARIN SODIUM, but still significant enough to appear in the safety profile.
In addition to anaemia, the following adverse reactions have been reported for ENOXAPARIN SODIUM:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 2,189 FDA reports for ENOXAPARIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 2.3% of all adverse event reports for ENOXAPARIN SODIUM, making it a notable side effect.
If you experience anaemia while taking ENOXAPARIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.